1/23
Looks like no tags are added yet.
An 18-year-old woman patient presents to your pharmacy with a question concerning her Humira. She plans to travel 6 hours in a car with friends to attend a concert of her local band. She is due to administer her Humira the next day. Which of the following strategies would be appropriate to store her Humira while traveling?
A
Freeze Humira overnight and keep in insulated container to thaw while driving. Do not administer Humira until completely thawed.
B
Remove Humira from refrigerator immediately prior to traveling and store at room temperature during travel. Refrigerate once able to and administer within 24 hours.
C
Remove Humira from refrigerator in original packaging immediately prior to traveling and store in original packaging in a cool carrier with ice packs to keep Humira between 36°F and 46°F (2°C to 8°C) throughout journey. Refrigerate once able to, provided temperature stays within range.
D
Humira is pegylated so it has improved tolerance to heat or cold compared to other tumor necrosis factor- α (TNF-α) antagonist. It is safe to use provided temperature is within range of 33°F to 68°F.
C (I disagree with explanations)
Per Rxprep:
do not shake or freeze, requires refrigeration, allow to reach RT before inj (15-30min); etanercept and adalimumab can be stored at RT for a max of 14d; do not refrigerate once warmed
Per the package insert, Humira must be refrigerated at 2°C to 8°C (36°F to 46° F). Do not freeze. Do not use if frozen even if it has been thawed. When traveling, Humira should be stored in a cool carrier with an ice pack. Protect the prefilled syringe from exposure to light. Store in original carton until time of administration.
Answer a is incorrect. Never freeze Humira (adalimumab). It cannot be used if it has been previously frozen and now thawed.
Humira is not pegylated, unlike certolizumab pegol (Cimzia). The added pegylation also does not safeguard against storage in unrefrigerated conditions, but rather the pegylation adds a longer duration of action allowing it to be given every 4 weeks.
Which of the following is only available as a subcutaneous injection?
A
Remicade
B
Flagyl
C
Xeljanz
D
Humira
D
Remicade (infliximab) is only available for intravenous injection.
Answer b is incorrect. Flagyl (metronidazole) is available in capsule, tablet, topical, and intravenous forms.
A 38-year-old male patient is newly diagnosed with mild to moderate Crohn disease (CD) confined to the ileum and ascending colon. What is the best recommendation for this patient?
A
Mesalamine enema 1 g PR at bedtime
B
Prednisone 40 mg orally daily
C
Certolizumab pegol 400 mg subcutaneously
D
Budesonide 9 mg orally daily
D
Oral budesonide is effective for the induction of remission of mild to moderate disease affecting the ileum or ascending colon. Budesonide undergoes first pass metabolism which limits systemic exposure and adverse effects.
Topical mesalamine enema would only be effective for left-sided disease that is distal to the splenic flexure. It would not be effective for disease the affects the ileum and ascending colon.
Answer b is incorrect. Systemic corticosteroid therapy is reserved for the induction of remission in moderate to severe CD.
Answer c is incorrect. TNF-α antagonists are reserved for the induction of remission for patients with moderate to severe CD or who are unresponsive to corticosteroid or therapy. It would not be appropriate to initiate a TNF-α antagonist for a patient with mild to moderate disease who is treatment-naïve.
Mesalamine is available in which of the following dosage forms and strengths? Select all that apply.
A
400-mg oral suspension
B
1000-mg rectal suppository
C
4-g rectal enema
D
500-mg extended-release oral capsule
E
800-mg delayed-release oral tablet
B, C, D, E
Canasa and its generic are available in 1000-mg rectal suppository formulation.
Answer c is correct. Rowasa and its generic are available as a 4-g rectal enema.
Answer d is correct. Pentasa is available as a 500-mg extended-release oral capsule.
Answer e is correct. Asacol and its generic are available as 800-mg delayed-release oral tablets.
A 56-year-old man, QC, has a history of Crohn disease (CD) and is maintained in remission with oral mesalamine of 800 mg daily and oral prednisone 30 mg daily. He is interested in trying weekly subcutaneous injections of methotrexate with a goal of discontinuing his prednisone therapy. Which monitoring parameters should be assessed prior to initiating and periodically during methotrexate therapy? Select all that apply.
A
Liver transaminases
B
Chest radiography
C
Complete blood count
D
Serum potassium
A, B, C
Methotrexate is associated with hepatotoxicity. Liver function tests, specifically liver transaminases, should be monitored in patients receiving methotrexate.
Answer b is correct.Methotrexate is associated with the development of pneumonitis. Chest radiography and pulmonary function tests should be assessed at baseline and periodically during methotrexate therapy.
Answer c is correct.Methotrexate is a folate antagonist that can cause bone marrow suppression. A complete blood count should be routinely monitored in patients receiving methotrexate.
Answer d is incorrect.Methotrexate is not commonly associated with alterations in serum potassium concentrations except in the instance of severe nephrotoxicity caused by methotrexate.
CH is a 42-year-old female patient with moderate to severe ulcerative colitis. After failure of infliximab, she presents with a new prescription for tofacitinib. Her current medication list includes: lisinopril, tacrolimus ointment, atorvastatin, levonorgestrel/ethinyl estradiol, and metformin. Which of the medications in CH's profile is most likely to interact with her new prescription of tofacitinib?
A
Lisinopril
B
Tacrolimus
C
Atorvastatin
D
Levonorgestrel
E
Metformin
B
Concurrent use of tacrolimus (including topical administration) with tofacitinib may lead to increased adverse/toxic effects of tofacitinib.
tofacitinib requires dose adjustment w/mod-strong CYP3A4 inducers and hep/renal impairment
Order the following formulations of mesalamine from least to most area of exposure within the gastrointestinal (GI) tract:
Canasa Rowasa Asacol Pentasa
Canasa: suppository
Rowasa: enema
Asacol: ER tab; Pentasa: ER capsules
A 38-year-old man with moderate to severe Crohn disease (CD) has been experiencing numerous relapses on his current medication regimen. He is taking azathioprine and infliximab for maintenance therapy. What changes would be best to make to his maintenance regimen?
A
Stop infliximab and initiate intravenous cyclosporine.
B
Stop infliximab and azathioprine and initiate dexamethasone.
C
Stop infliximab and azathioprine and initiate vedolizumab.
D
Continue azathioprine and infliximab and begin natalizumab.
C
.Vedolizumab is an anti-integrin antibody that may be used in patients who fail immunomodulator and tumor necrosis factor-α (TNF-α) antagonist therapies. It is now preferred over natalizumab due to the reduced risk of progressive multifocal leukoencephalopathy (PML).
The anti-integrins, vedolizumab and natalizumab, should not be used in combination with TNF-α antagonists.
Cyclosporine is only used in severe UC exacerbations to delay time to colectomy and is not appropriate as a maintenance therapy.
A 38-year-old female patient with Crohn disease (CD) is prescribed Humira for treatment of severe symptoms. Which counseling point is best to provide to this patient prior to starting this therapy?
A
Correct number of tablets to take on a daily basis.
B
The next dose should be given in 8 weeks.
C
Proper injection technique.
D
Monitor for development of diarrhea.
C
Since Humira is administered by subcutaneous injection and is available as a single-dose syringe or a pen device, that patient should be instructed on how to use the formulation and administer the injection properly. The manufacturer medication guide has detailed instructions which can be used to educate patients on this process.
Humira is not commonly associated with development of diarrhea.
Which of the following medications is indicated for the treatment of ulcerative colitis, but not Crohn disease?
A
Golimumab
B
Infliximab
C
Adalimumab
D
Ustekinumab
A
.Golimumab is currently approved by the FDA for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. It has not been approved for Crohn disease.
Which of the following drug-drug pairings represents a significant interaction that suggest therapy change?
A
Infliximab and 6-mercaptopurine
B
Methotrexate and metronidazole
C
Allopurinol and azathioprine
D
Golimumab and gabapentin
C
.Allopurinol may increase serum concentrations of the active metabolite (6-mercaptopurine) of azathioprine. Other therapies should be considered.
Answer a is incorrect. Though both augment the immune system. It is appropriate to consider usage of both infliximab and thiopurines to induce remission in moderate to severe inflammatory bowel disease (IBD).
A 41-year-old woman with ulcerative colitis (UC) affecting most of her colon (pancolitis) has been taking balsalazide 6.75 g/d orally for 2 years and prednisone 40 mg/d orally for 1 year. When the dose of prednisone is reduced to less than 40 mg, the patient develops fever, abdominal pain, and five or six bloody bowel movements a day. Which modification to this patient's drug regimen is the most appropriate at this time?
A
Initiate therapy with methotrexate 25 mg intramuscularly once weekly.
B
Initiate infliximab 5 mg/kg intravenous infusion.
C
Change balsalazide to sulfasalazine orally 6 g/d.
D
Add mesalamine suppository 1000 mg rectally once daily.
B
This patient's CD is steroid-dependent. Infliximab therapy may result in steroid-sparing effects and allow for reduction of the steroid dose or discontinuation of the steroid.
Answer a is incorrect.Methotrexate is effective for the maintenance of remission of Crohn disease (CD) and would not be appropriate to use for this patient's UC.
Answer c is incorrect.Balsalazide and sulfasalazine are both aminosalicylates with similar effectiveness, so switching to sulfasalazine would not improve this patient's symptoms.
Answer d is incorrect. This patient is already receiving an oral mesalamine formulation for his pancolitis. A mesalamine suppository would be appropriate if the patient was experiencing UC, but it would not be likely to reduce the patient's dependence on his steroid therapy.
TP has been treated for his ulcerative colitis with adalimumab for 6 months. He has failed to experience an improvement in his symptoms. In this time he received appropriate loading and maintenance dosing and acknowledges proper adherence. Prior to his next dose therapeutic drug monitoring is performed. TP's labs demonstrate therapeutic levels of infliximab, no detectable level of antidrug antibodies to infliximab present, and high levels of inflammatory markers. What is the best strategy in this patient?
A
Discontinue adalimumab and start golimumab.
B
Continue adalimumab and add ustekinumab.
C
Discontinue adalimumab and start vedolizumab.
D
Continue adalimumab and decrease duration to administration every 7 days.
C
Suboptimal response despite therapeutic levels of medication suggests a drug class failure. The patient is not likely to respond to another TNF-α antagonist. Discontinuation of TNF-α antagonist and initiation of anti-integrin agent in vedolizumab is appropriate.
JP is a 32-year-old male patient with a diagnosis of mild to moderate Crohn disease of the ileum. He is now trying to titrate off corticosteroids and would like to try methotrexate therapy. What is the appropriate route and dose of methotrexate in this patient?
A
Intravenous (IV) infusion of 25 mg weekly
B
Subcutaneous (SQ) injection of 25 mg daily
C
SQ injection of 25 mg weekly
D
Intramuscular injection of 15 mg three times weekly
C
.Methotrexate is initiated at 25 mg SQ weekly then may consider decrease down to 15 mg weekly SQ if symptom-free for 4 months.
.Methotrexate is not given IV for CD.
Which of the following medications is appropriate as an initial therapy in mild ulcerative colitis of the distal colon?
A
Entyvio
B
Trexall
C
Rowasa
D
Tysabri
C
Rowasa (mesalamine) is an enema preparation effective for mild to moderate ulcerative colitis of the distal colon.
Answer a is incorrect.Vedolizumab is indicated for both moderate to severe disease caused by Crohn disease and ulcerative colitis. It is not indicated as initial therapy in mild disease.
Answer b is incorrect.Methotrexate is indicated for Crohn disease. It has not been shown to be effective in ulcerative colitis.
Answer d is incorrect. Tysabri (natalizumab) is indicated for moderate to severe Crohn disease and not ulcerative colitis. Use is limited due to risk of adverse effects.
A 29-year-old patient with moderate-to-severe Crohn disease has been treated with infliximab 5 mg/kg for 4.5 years. Infliximab was his first and only treatment for his Crohn disease. In the past three cycles of infliximab, the patient has reported a "wearing off" effect of infliximab 10 days prior to the next dose. These increased symptoms include diarrhea, aphthous ulcers, and abdominal pain 6-7 (out of 10, with 10 being the worst pain he has ever felt). He undergoes a colonoscopy 1 week prior to his next scheduled infliximab dose, which reveals deep ulcers in the ileum, distal, and proximal colon. There is a mild stricture of the valve connecting the ileum and colon. Labs are also performed on the same day and demonstrate subtherapeutic levels of infliximab, elevated levels of antidrug antibodies to infliximab present, and high levels of inflammatory markers. What is the best strategy in this patient?
A
Supplement with both oral and rectal mesalamine products to induce remission, then decrease to just rectal mesalamine.
B
Discontinue infliximab and start golimumab.
C
Discontinue infliximab and start adalimumab.
D
Increase infliximab to 7.5 mg/kg and redraw trough level before next infusion.
C
Patient has a subtherapeutic level of infliximab with high levels of antidrug antibodies. This suggests immune-mediated pharmacokinetic (PK) failure. The patient should be switched to another drug within the same class (tumor necrosis factor [TNF]-α antagonist).
.Golimumab is not indicated in Crohn disease.
Which of the following represents correct storage and handling of medications in inflammatory bowel disease (IBD)?
A
Methotrexate is a hazardous drug due to teratogenicity. Handling of tablets requires protective equipment such as gloves.
B
Golimumab should be refrigerated at 36°F to 46°F (2°C to 8°C). Shake prior to administration.
C
Thiopurine in tablet form may be safely handled without any protective gear such as gloves.
D
Vedolizumab vials must be stored between 59°F and 77°F (15°C to 25°C) in outer carton to protect from light.
A
Gloves should be worn when receiving, handling, administration, and disposal of methotrexate.
Answer b is incorrect.Golimumab should never be shaken as it may reduce stability of the medication.
Answer c is incorrect. Gloves should be worn when receiving, handling, administration, and disposal of thiopurines.
Answer d is incorrect. Unopened vedolizumab vial should be stored in a refrigerator 36°F to 46°F (2°C to 8°C). Keep the vial in the outer carton to protect from light.
A 21-year-old woman has been able to maintain remission of her ulcerative colitis (UC) for the past year with the use of oral mesalamine, oral azathioprine, and intravenous infliximab therapy. This patient is not up to date with her vaccines. Which of the following vaccines are contraindicated in this patient? Select all that apply.
A
Injectable influenza vaccine
B
Human papilloma virus (HPV)
C
Measles, mumps, rubella (MMR)
D
Tetanus, diphtheria, pertussis (Tdap)
C
The MMR vaccines are a live-attenuated viral vaccine, making it contraindicated in patients who are immunosuppressed.
Answer a is incorrect. The injectable inactivated viral influenza vaccine is not a live vaccine and would therefore be appropriate to administer on an annual basis for this patient. A previously available intranasal influenza vaccine was a live-attenuated viral vaccine. Because this patient is receiving multiple immunosuppressive treatments, live vaccines are contraindicated.
Answer b is incorrect. HPV vaccine is an inactivated viral vaccine. Three doses are recommended for administration to patients younger than 26 years, and would be appropriate for this patient.
Answer d is incorrect. Tdap is an inactivated viral vaccine that is recommended for use in immunosuppressed patients and should be administered to this patient.
EJ is a 27-year-old female patient who presents to your clinic. She was diagnosed with moderate to severe Crohn disease 1 month ago. EJ was initiated on prednisone (40 mg daily with a 5-mg daily taper reduction each week) and azathioprine. She is frustrated as she and her husband are thinking of trying to start a family, and she read that azathioprine may have negative impact on the pregnancy. Her male cousin was able to transition off azathioprine for his Crohn disease by changing to methotrexate. Which of the following are appropriate counseling points to EJ? Select all that apply.
A
Azathioprine does cross the placenta. There is data that suggests that patients on azathioprine may continue maintenance therapy during pregnancy.
B
Methotrexate is teratogenic and would be contraindicated in pregnant patients. A different therapy would be recommended.
C
Methotrexate is not recommended as treatment for Crohn disease in female patients as the difference in volume of distribution relative to male patients makes it unlikely to reach levels necessary to treat Crohn disease adequately.
D
Azathioprine offers an improved safety profile due to the lack of risk of bone marrow suppression and hepatotoxicity compared to methotrexate.
A, B
.Azathioprine does cross the placenta; however, evidence in the Toronto consensus guidelines in 2016 suggests that patients in CD and UC may continue azathioprine during pregnancy.
Answer b is correct.Methotrexate is teratogenic and should be avoided in women of child-bearing age. If therapy is deemed necessary, then reliable forms of contraception should be used.
Answer c is incorrect.Methotrexate can be used effectively as a steroid-sparing maintenance therapy in Crohn disease in both male and female patients.
Answer d is incorrect. Both azathioprine and methotrexate carry risks for bone marrow suppression and hepatotoxicity necessitating need for monitoring.
DB is a 57-year-old male patient currently being treated for his UC with 6-mercaptopurine. He complains that his symptoms are not controlled on his current therapy. His physician is considering initiating DB on infliximab. Which of the following conditions is considered a contraindication to receiving a tumor necrosis factor-α (TNF-α) antagonist? Select all that apply.
A
Asthma
B
Migraine headaches
C
NYHA III heart failure
D
Latent tuberculosis (TB)
C, D
Advanced heart failure (NYHA III or IV) is a contraindication to receiving TNF-α antagonists as these agents may worsen heart failure.
Answer a is incorrect. Asthma or chronic obstructive pulmonary disease (COPD) is not considered contraindications to therapy.
Answer b is incorrect. Migraine headache is not considered a contraindication to therapy. Neurologic disorders, such as optic neuritis or demyelinating diseases, would be potential contraindications.
Answer d is correct. Since TNF-α antagonists are associated with development of opportunistic infections, patients should be tested for TB prior to initiation of a TNF-α antagonist. Presence of TB would indicate treatment of the infection (latent or active) prior to starting therapy with a TNF-α antagonist.
BQ is a 54-year-old male patient who presents to your clinic with long-standing Crohn disease. Due to a lack of health insurance and failure with methotrexate, BQ has been managed with 6-mercaptopurine and prednisone 20 mg daily for the past 4 years. He is not adherent with pneumococcal vaccination recommendations. Which of the following would be appropriate strategies for this patient at the clinic today? Select all that apply.
A
Immediately discontinue prednisone due to risk of developing diabetes.
B
Refer for bone mineral density screening and initiation of calcium and vitamin D if applicable.
C
Administer PCV13 vaccine.
D
Administer PPSV23 vaccine.
B, C
Patients who receive prolonged courses of corticosteroids should be screened for bone mineral density loss, and calcium and vitamin D supplementation is appropriate pending density screening.
Answer c is correct. This patient requires pneumococcal vaccination. Give one dose of PCV13 and two doses of PPSV23. Administer PCV13 at this visit, then give the first PPSV23 dose at least 8 weeks later. Give the second dose of PPSV23 at least 5 years after the first dose of PPSV23. Guidelines may have changed
A patient receiving Tysabri for Crohn disease (CD) develops mental status changes after 24 weeks of therapy. This may indicate development of which adverse effect of Tysabri?
A
Progressive multifocal leukoencephalopathy
B
Central pontine myelinolysis
C
Cerebrovascular accident
D
Multi-infarct dementia
A
Tysabri (natalizumab) is associated with development of progressive multifocal leukoencephalopathy as a potential adverse neurologic effect. For this reason, prescribers must enroll in the manufacturer's prescribing program in order to prescribe this agent. Patients should also be closely monitored for signs or symptoms of neurologic changes while receiving therapy.
Answer b is incorrect. Central pontine myelinolysis is an adverse neurologic event associated with nerve demyelination, often due to rapid correction of hyponatremia.
Answer c is incorrect. Tysabri (natalizumab) is not commonly associated with development of cerebrovascular accident as a potential adverse neurologic effect.
Answer d is incorrect. Multi-infarct dementia is a neurologic disorder associated with having multiple strokes over time, many of which are clinically silent. This is not a condition associated with natalizumab use.
JZ is a 21-year-old male patient (60 kg) who was diagnosed with moderate to severe ulcerative colitis. He is being started on infliximab. What is the appropriate initial dose of infliximab to prepare intravenously?
A
240 mg
B
300 mg
C
500 mg
D
600 mg
B
300 mg represents 5 mg/kg.
BZ is a 29-year-old male Crohn disease patient who has been experiencing loss of effectiveness to his certolizumab pegol injections over the past 6 months. He has previously taken infliximab and adalimumab. BZ experienced periods of clinical remission with each medication before encountering a similar loss of effectiveness and ultimately discontinuing each medication. He is ready to try a medication not in the tumor necrosis factor-α (TNF-α) antagonist class. He is prescribed ustekinumab; however, he is completely unaware of this medication since he has only been on TNF-α antagonists for his Crohn disease. What would be appropriate counseling points to discuss with BZ prior to initiating ustekinumab? Select all that apply.
A
The first dose of ustekinumab is a weight-based intravenous infusion.
B
It is dosed every 8 weeks.
C
Ustekinumab carries similar risks to TNF-α antagonist, such as development of serious infections and infusion reactions.
D
Similar to certolizumab, ustekinumab is a humanized monoclonal antibody; however, it has a different antibody target.
A, B, C, D
The first dose is a weight-based infusion. This is followed by subcutaneous (SQ) dosing 90 mg every 8 weeks.
. Both products are humanized monoclonal antibodies. Certolizumab is a TNF-α antagonist and ustekinumab targets interleukin (IL)-12/IL-23. disagree, Stelara is fully human